文章：

结直肠癌的社会负担与医疗成本

Social Burden and Healthcare Costs of Colorectal Cancer

原文发布日期：17 November 2025

DOI: 10.3390/cancers17223678

类型: Article

开放获取: 是

英文摘要：

Background: Colorectal cancer is the third most common malignant cancer, and according to the predictions, the estimated number of new cases will grow in coming years. Therefore, an increase in the costs of the disease will increase as well. Therefore, there is a need for continuous research on the costs and the economic burden of colorectal cancer and for reviewing the research results systematically. The current paper presents a literature review regarding the state of knowledge about the costs of treatment and the economic burden of colorectal cancer. Methods: A total of 20 papers from MEDLINE database were included in the final analysis. The review is focused on the estimates of direct costs, i.e., treatment of colorectal cancer, screening after treatment, and indirect costs. Results: the vast majority of studies were focused on direct costs only, which clearly shows the literature gap. Metastatic colorectal cancer was the most frequent category for various treatment cost evaluation. The costs associated with the use of bevacizumab in various combinations were calculated most frequently. Conclusions: Further summarizing review and developing a methodology for standardized comparisons is necessary, specifically addressing indirect costs.

摘要翻译： 

背景：结直肠癌是第三大常见恶性肿瘤，据预测未来几年新增病例数将持续增长，相应的疾病治疗成本也将随之上升。因此，有必要持续开展结直肠癌治疗成本与经济负担研究，并对现有研究成果进行系统性梳理。本文旨在通过文献综述，梳理结直肠癌治疗成本与经济负担的研究现状。方法：最终纳入MEDLINE数据库中20篇文献进行分析。本综述重点关注直接成本（包括结直肠癌治疗、治疗后筛查）与间接成本的评估研究。结果：绝大多数研究仅聚焦于直接成本，这凸显了该领域的研究空白。转移性结直肠癌成为各类治疗成本评估中最常见的分类，其中贝伐珠单抗联合用药方案的成本测算频率最高。结论：未来需进一步开展综合性综述研究，并建立标准化比较方法学体系，尤其应加强对间接成本的评估。

原文链接：

Social Burden and Healthcare Costs of Colorectal Cancer